Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2003, for A.P. Pharma, Inc. (Note: The request metadata listed "Heron Therapeutics," but the filing text identifies the registrant as A.P. Pharma, Inc.). The company develops patented polymer-based delivery systems to enhance pharmaceutical safety and effectiveness. Operations are confined to a single business segment. The financial statements include the company and its subsidiary, APS Analytical Standards, Inc., through the date of sale in February 2003.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | As of Sep 30, 2003 |
|---|---|---|---|
| Total Revenues | $1,268,000 | $3,490,000 | N/A |
| Net Loss | $(1,058,000) | $(2,985,000) | N/A |
| Operating Loss | $(1,235,000) | $(5,094,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,473,000 |
| Marketable Securities | N/A | N/A | $9,620,000 |
| Total Assets | N/A | N/A | $14,679,000 |
| Total Current Liabilities | N/A | N/A | $2,027,000 |
| Accumulated Deficit | N/A | N/A | $(74,220,000) |
Liquidity: The company holds $11.093 million in cash, cash equivalents, and marketable securities. Management expects these resources to be sufficient to meet cash needs for at least two years.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased to $1.268 million for the three months ended September 30, 2003, from $1.041 million in the same period in 2002. Royalties rose to $1.149 million from $935,000, driven by continued sales growth of Retin-A Micro following a new low-dose formulation launch.
- Expense Increases: Research & development (R&D) expenses increased to $6.391 million for the nine months ended September 30, 2003, from $5.243 million in 2002. This increase is attributed to Biochronomer studies, preclinical safety studies for the APF112 formulation, and manufacturing costs for GMP product for human clinical trials.
- Discontinued Operations: The company recorded a gain of $1.759 million on the disposition of discontinued operations for the nine months ended September 30, 2003, compared to $432,000 in 2002. This primarily reflects the sale of the Analytical Standards division in February 2003.
- Interest Income: Net interest income decreased to $197,000 for the nine months ended September 30, 2003, from $491,000 in 2002, due to lower interest rates and lower average cash balances.
Outlook, Risks, and Management Commentary
- Clinical Progress: In August 2003, the company received FDA clearance to initiate human clinical studies for APF112, a drug designed to provide 24 to 36 hours of pain relief following surgery. Phase II trials for post-surgical pain have been initiated.
- Capital Requirements: Future funding needs depend on royalties, potential joint ventures for the APF112 project, and the progress of clinical trials. The company anticipates no material changes to its business plan requiring immediate external financing.
- Risks: Key risks include uncertainty regarding the timely development, approval, and launch of new products; the establishment of new corporate alliances; and the progress of R&D programs. Approximately 75% of accounts receivable are concentrated with two pharmaceutical customers.
- Accounting Changes: The company adopted EITF 00-21 regarding revenue arrangements with multiple deliverables, which did not have a material effect on financial results. FIN 46 regarding variable interest entities was also adopted with no material effect.
Investor Verification Checklist
- Verify the status and timeline of the Phase II clinical trials for APF112 and the potential for a joint venture partner to share costs.
- Confirm the sustainability of royalty revenue from Retin-A Micro and Carac, given the concentration of receivables with two major customers.
- Monitor cash burn rates relative to the $11.1 million in liquid assets to ensure the "two-year" runway remains valid.
- Review the terms of the Analytical Standards sale, specifically the royalty structure (15% for year one, declining thereafter) and any remaining earn-out obligations.
- Assess the impact of the $209,000 severance charges recorded related to the Analytical Standards sale on future operating expenses.